Table 4.
Overview of trials for locally advanced HER2-positive gastric cancer.
| Study | Phase | Intervention | Endpoint |
|---|---|---|---|
|
NCT05504720 PHERFLOT |
II | trastuzumab plus pembrolizumab plus FLOT | DFS, pCR |
| NCT05715931 | II | trastuzumab plus toripalimab plus FLOT | pCR |
| NCT04819971 | II | trastuzumab plus tislelizumab plus S-1/oxaliplatin/docetaxel | pCR |
|
NCT05771584 CONERSTONE3 |
II | AST-301 vaccine after standard adjuvant treatment (Taiwan) in HER2 overexpression/low | Safety, immunologic efficacy |
| NCT05034887 | II | T-DXd neoadjuvant in HER2 overexpression/low | MPR |
| NCT06155383 | II | Disitamab vedotin plus toripalimab ± XELOX vs. XELOX |
pCR |